Visfatin −948G/T and resistin −420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases

Genome ◽  
2014 ◽  
Vol 57 (5) ◽  
pp. 259-266 ◽  
Author(s):  
Tarek M.K. Motawi ◽  
Olfat G. Shaker ◽  
Maha M. El-Sawalhi ◽  
Zeinab M. Abdel-Nasser
Keyword(s):  
Cardiovascular Diseases ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Causes of death, incidence and risk factors of cardiovascular diseases in Thai type 2 diabetic patients: a 5-year follow-up study

2003 ◽  
Vol 60 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Rattana Leelawattana ◽  
Chatchalit Rattarasarn ◽  
Apiradee Lim ◽  
Supamai Soonthornpun ◽  
Worawong Setasuban
Keyword(s):  
Risk Factors ◽  
Cardiovascular Diseases ◽  
Causes Of Death ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Follow Up Study ◽  
Type 2 Diabetic

Cystatin C is a Valuable Marker for Predicting Future Cardiovascular Diseases in Type 2 Diabetic Patients

2008 ◽  
Vol 32 (6) ◽  
pp. 488 ◽  
Author(s):  
Seung-Hwan Lee ◽  
Kang-Woo Lee ◽  
Eun Sook Kim ◽  
Ye Ree Park ◽  
Hun-Sung Kim ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Cystatin C ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Valuable Marker ◽  
Type 2 Diabetic

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Sign in / Sign up

Export Citation Format

Share Document